Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pilar Hernández Campo"'
Autor:
Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 11, Iss 1, Pp e2019016-e2019016 (2019)
BACKGROUND: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remissio
Externí odkaz:
https://doaj.org/article/81b4fa5b2a224f32948fabdc5eced125
Autor:
Alicia Arenas Cortés, Rosa Ayala Diaz, Pilar Hernández-Campo, Julián Gorrochategui, Daniel Primo, Alicia Robles, María Luz Morales, Joan Ballesteros, Inmaculada Rapado, Miguel Gallardo, María Linares, Joaquín Martínez-López
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity. In an attempt to improve response and avoid the
Externí odkaz:
https://doaj.org/article/aded39ba73634bc3a45a4b798400a755
Autor:
Belén Blanco, José A. Pérez-Simón, Luis I. Sánchez-Abarca, Teresa Caballero-Velazquez, Silvia Gutierrez-Cossío, Pilar Hernández-Campo, María Díez-Campelo, Carmen Herrero-Sanchez, Concepción Rodriguez-Serrano, Carlos Santamaría, Fermín M. Sánchez-Guijo, Consuelo del Cañizo, Jesús F. San Miguel
Publikováno v:
Haematologica, Vol 94, Iss 7 (2009)
Background In vitro depletion of alloreactive T cells using the proteasome inhibitor bortezomib is a promising approach to prevent graft-versus-host disease after allogeneic stem cell transplantation. We have previously described the ability of borte
Externí odkaz:
https://doaj.org/article/4f97eaf78a574f4b88980ce89c2d40b4
Autor:
Antonio Garcia-Gomez, Enrique M Ocio, Edvan Crusoe, Carlos Santamaria, Pilar Hernández-Campo, Juan F Blanco, Fermin M Sanchez-Guijo, Teresa Hernández-Iglesias, Jesús G Briñón, Rosa M Fisac-Herrero, Francis Y Lee, Atanasio Pandiella, Jesús F San Miguel, Mercedes Garayoa
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34914 (2012)
BackgroundBone loss, in malignant or non-malignant diseases, is caused by increased osteoclast resorption and/or reduced osteoblast bone formation, and is commonly associated with skeletal complications. Thus, there is a need to identify new agents c
Externí odkaz:
https://doaj.org/article/b5156085cd814cbb9ad781f61ac1696e